来自MSN29 天
FDA grants fast track status to Pyxis’ PYX-201
The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC), PYX-201, to treat adults with recurrent or metastatic head and ...
来自MSN15 天
Atsena’s ATSN-201 gains FDA fast track status for XLRS treatment
Atsena Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, ATSN-201, to treat X-linked retinoschisis (XLRS).